Subscribe To
Idorsia notes potential $440.8M Asia licensing deal to extend cash runway amid slow Quviviq sales
Swiss biopharma Idorsia gave out few details Tuesday about a potential $440.8 million (400 million CHF) deal with an unnamed company that would include licensing rights to some of Idorsia’s products … Read Full Story at source (may require registration) The post Idorsia notes potential $440.8M Asia licensing deal to extend cash runway amid slow Quviviq sales appeared first on ForexTV...
Read More
Posted: Jun 6 2023, 12:00
Author Name: forextv
Views: 081331